

Facility Name:	
Patient Name:	DOB:
Standing Order Administration of Respiratory Syncytial Virus Vaccine (RSV) in Adults <i>*Pharmacy Use Only*</i>	Date:
	Vaccine Products ⁽¹⁾ and Cost Per Dose: -Abrysvo (RSVPreF, unadjuvanted protein vaccine): _____ -Arexvy (RSVPreF3, protein vaccine with AS01 adjuvant): _____
Purpose	The Canadian National Advisory Committee on Immunization (NACI) strongly recommends vaccination for Adults 60 years of age and older who are residents of nursing homes and other chronic care facilities ⁽²⁾ to reduce morbidity and mortality from Respiratory Syncytial Virus (RSV).
What is RSV?	RSV is transmitted via infected droplets in the air. These droplets damage the airway lining and increase the risk of pneumonia, resulting in symptoms such as wheezing, shortness of breath, and hospitalization for oxygen supplementation. RSV infections are common in older adults, and their incidence increases with age. A Canadian population-based study of RSV-associated adult hospitalizations found that more than half of those hospitalized for RSV resided in long-term care or received home care in the year before admission ⁽³⁾ .
Vaccine Effectiveness	Vaccination is safe and effective at preventing severe RSV disease, hospitalization and death ⁽⁴⁾ .
Route of Administration	Intramuscular injection of 0.5 mL. No booster is currently recommended, but that may change over time.
Timing of Administration	Eligible adults who have not previously received RSV vaccination may be vaccinated at any time of year, but vaccination will have the most benefit if administered in late summer or early fall, just before the RSV season
Based on the information above, I would like to: ☐ Receive an RSV Vaccination Consent Form and discuss the RSV Vaccination in more detail with my Clinical Consultant Pharmacist (CCP) beforehand. ☐ Refuse the RSV Vaccine	
Resident and/or POA Name	
Signature	

1. Health Canada approves all currently available RSV vaccination products for LTC residents and is safe and equally effective at preventing RSV disease and complications. The community pharmacy will supply the product available on the day of administration*
2. Statement on the prevention of respiratory syncytial virus disease in older adults (NACI)
<https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-statement-prevention-rsv-disease-older-adults.html#s5.1>
3. Mac S, Shi S, Millson B, et al. Burden of illness associated with respiratory syncytial virus (RSV)-related hospitalizations among adults in Ontario, Canada: A retrospective population-based study. Vaccine. 2023 Aug;41(35): 5141-5149.
<http://doi.org/10.1016/j.vaccine.2023.06.071>
4. Older Adult High-Risk Respiratory Syncytial Virus (RSV) Vaccine Program Fact Sheet - Vaccine Recipients
<https://www.ontario.ca/files/2024-08/moh-older-adult-high-risk-rsv-fact-sheet-v4-0-vaccine-recipients-en-2024-08-16.pdf>